Bronconex Acticap

Land: New Zealand

Språk: engelsk

Kilde: Medsafe (Medicines Safety Authority)

Aktiv ingrediens:

Mometasone furoate 400ug (anhydrous)

Tilgjengelig fra:

Organon (New Zealand) Limited

INN (International Name):

Mometasone furoate 400 µg (anhydrous)

Dosering :

400 mcg/dose

Legemiddelform:

Powder for inhalation

Sammensetning:

Active: Mometasone furoate 400ug (anhydrous) Excipient: Lactose

Enheter i pakken:

Inhaler, metered, DPI, (sample), 14 dose units

Klasse:

Prescription

Resept typen:

Prescription

Produsert av:

MSD International GmbH (Singapore Branch)

Indikasjoner:

Bronconex Acticap is indicated for prophylactic therapy in the management of patients with asthma of all severities, including patients who have been dependent upon either inhaled or systemically administered corticosteroids and non-corticosteroid-dependent patients inadequately controlled on other drug regimens.

Produkt oppsummering:

Package - Contents - Shelf Life: Inhaler, metered, DPI, (sample) - 14 dose units - 18 months from date of manufacture stored at or below 25°C - Inhaler, metered, DPI - 30 dose units - 18 months from date of manufacture stored at or below 25°C - Inhaler, metered, DPI - 60 dose units - 18 months from date of manufacture stored at or below 25°C

Autorisasjon dato:

2000-12-05